Drugs and Devices

FDA approves drug for rare metabolic disorder

On Sept. 4, the U.S. Food and Drug Administration (FDA) approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary orotic aciduria, a rare metabolic disorder that has been reported in about 20 patients worldwide.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares